EZH2 and medical procedure: The related pharmacodynamic study showed that 3-Deazaneplanocin A (DZNep), a known EZH2 inhibitor, can induce apoptosis in cancer cells, including prostate cancer36, breast cancer53 and acute myeloid leukemia54.